. "2012-04-01+02:00"^^ . " synthesis" . . . . "http://www.isvav.cz/projectDetail.do?rowId=NT13346"^^ . . "2015-12-31+01:00"^^ . . "13"^^ . "NT13346" . "13"^^ . "2015-01-22+01:00"^^ . " in vitro testing" . "0"^^ . . . "1"^^ . " MDR resistance" . "1"^^ . . "Jedn\u00E1 se o aplikovan\u00FD mezioborov\u00FD v\u00FDzkum, sm\u011B\u0159uj\u00EDc\u00ED k potla\u010Den\u00ED extensivn\u011B se roz\u0161i\u0159uj\u00EDc\u00ED mykobakteri\u00E1ln\u00ED infekce, v\u010Detn\u011B multil\u00E9kov\u011B rezistentn\u00EDch kmen\u016F. \u0158e\u0161en\u00ED projektu vych\u00E1z\u00ED z molekulov\u00E9ho modelov\u00E1n\u00ED (in silico), synt\u00E9zy nov\u00FDch navr\u017Een\u00FDch l\u00E1tek, modelace prol\u00E9\u010Div zvy\u0161uj\u00EDc\u00EDch biodostupnost, pr\u016Fnik lipofiln\u00ED mykobakteri\u00E1ln\u00ED membr\u00E1nou, farmakogenomiky, klonov\u00E1n\u00ED enzym\u016F a jejich vyu\u017Eit\u00ED k hled\u00E1n\u00ED mechanism\u016F p\u016Fsoben\u00ED (docking). Hodnocen\u00ED in vitro bude prov\u00E1d\u011Bno na lidsk\u00FDch patogenech, kmenech Mycobacterium tuberculosis, avium a kansasi\u00ED izolovan\u00E9m od pacient\u016F. Enzymov\u00E9 c\u00EDlen\u00ED pat\u0159\u00ED k modern\u00EDm progresivn\u00EDm metod\u00E1m a bude prov\u00E1d\u011Bno na t\u0159ech naklonovan\u00FDch enzymech (Inh, Icl, MenB)." . "tuberculosis" . " enzyme targeting" . . . "Design a enzymov\u00E9 c\u00EDlen\u00ED nov\u00FDch antibakteri\u00E1ln\u011B \u00FA\u010Dinn\u00FDch slou\u010Denin v\u016F\u010Di multil\u00E9kov\u011B rezistentn\u00EDm kmen\u016Fm" . "2014-03-21+01:00"^^ . "Design and enzyme targeting of antibacterial active compounds against multidrug resistant strains"@en . . . "This is an interdisciplinary applied research, aimed at suppressing extensively growing mycobacterial infections, including resistant and multidrug resistant strains. The project is based on a molecular modelling (in silico), synthesis of newly designed prodrugs directed to the increasing bioavailability, the penetration through the lipophilic mycobacterial membrane, pharmacogenomics, cloning enzymes and their use to search for mechanisms of action (docking). In vitro evaluation will be performed on human pathogenic strains of Mycobacterium tuberculosis, M. avium and M. kansasii isolated from patients. Enzyme targeting is one of the progressive methods and will be carried out on three cloned mycobacterial enzymes (InhA, ICL, MenB)."@en . . " docking" . . . . "tuberculosis; synthesis; in vitro testing; enzyme targeting; MDR resistance; docking, molecular modelling"@en .